KREBS BIOCHEMICALS & IND
- Market cap
- ₹122 cr
- ISIN
- INE268B01013
- Series
- EQ
- Listed on NSE
- 03 Jan 1996
- Face value
- ₹10
- F&O
- No
Earlier name: Krebs Biochemicals Limited (until 27 Oct 2016).
Source: NSE equity master · as of 31 Oct 2026 · market cap = shares (30 Sept 2026 filing) × close
Standalone · last four quarters to 2026-09-30 · balance sheet 2026-09-30 · tap a tile for the formula
Promoter share by quarter · source: NSE shareholding filings (XBRL). DIIs include mutual funds and insurers.
Quarterly results · Standalone · latest 30 Sept 2026
filed 29 Oct 2026, 02:11 pm IST| ₹ crore | Jun 26* | Sept 26* |
|---|---|---|
| Revenue | 7 | 6 |
| Other income | 0 | 0 |
| Total expenses | 10 | 11 |
| Operating margin | 11.8% | -33.3% |
| Finance costs | 2 | 2 |
| Depreciation | 2 | 2 |
| Profit before tax | -2 | -5 |
| Tax | 0 | 0 |
| Net profit | -2 | -5 |
| Net margin | -35.6% | -93.2% |
| EPS (₹) | -1.15 | -2.50 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison